Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 12/20 | 0.44 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | IKBKB | O14920 | 2/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | KMO | O15229 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3131607 | 0.78 | SCN9A (0.59) | SCN9AMAPTIKBKBKMO | |
| SCHEMBL1385399 | 0.76 | SCN4A (0.59) | TLR8SCN9ABCL2L1MCL1KDM4E | |
| SCHEMBL12780756 | 0.75 | TLR8 (0.67) | TLR8BCL2L1MCL1KDM4ESMN1; SMN2 | |
| SCHEMBL3125837 | 0.75 | SCN9A (0.55) | SCN9AMAPT | |
| SCHEMBL3135653 | 0.73 | IKBKB (0.55) | SCN9AKDM4EMAPTIKBKB | |
| SCHEMBL3131946 | 0.73 | SCN9A (0.59) | SCN9AMAPTKMO | |
| SCHEMBL3129126 | 0.73 | SCN4A (0.57) | SCN9AMAPTIKBKBKMO | |
| SCHEMBL14264193 | 0.73 | TLR8 (0.55) | TLR8BCL2L1MCL1KDM4ESMN1; SMN2 | |
| SCHEMBL3133736 | 0.72 | MAPT (0.52) | MCL1SMN1; SMN2MAPTIKBKBKMO | |
| SCHEMBL14264190 | 0.72 | MAPT (0.55) | TLR8BCL2L1MCL1MAPTHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1265866-B1 | ARYL SUBSTITUTED PYRIDINES, PYRIMIDINES, PYRAZINES AND TRIAZINES AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2010-07-21 | — | — | EP | claimed |
| US-6867210-B2 | Aryl substituted pyrimidines | EURO-CELTIQUE S.A. (LU) | 2005-03-15 | — | — | US | claimed |
| US-20040192691-A1 | Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof | EURO-CELTIQUE S.A. | 2004-09-30 | — | — | US | claimed |
| EP-1265866-A2 | ARYL SUBSTITUTED PYRIDINES, PYRIMIDINES, PYRAZINES AND TRIAZINES AND THE USE THEREOF | Euro-Celtique S.A. (LU) | 2002-12-18 | — | — | EP | claimed |
| US-20020040025-A1 | Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof | PURDUE PHARMA L.P. | 2002-04-04 | — | — | US | claimed |
| WO-2001068612-A2 | ARYL SUBSTITUTED PYRIDINES, PYRIMIDINES, PYRAZINES AND TRIAZINES AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2001-09-20 | — | — | WO | claimed |
| EP-1265866-B1 | ARYL SUBSTITUTED PYRIDINES, PYRIMIDINES, PYRAZINES AND TRIAZINES AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2010-07-21 | — | — | EP | disclosed |
| US-6867210-B2 | Aryl substituted pyrimidines | EURO-CELTIQUE S.A. (LU) | 2005-03-15 | — | — | US | disclosed |
| US-20050043305-A1 | Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof | EURO-CELTIQUE S.A. (LU) | 2005-02-24 | — | — | US | disclosed |
| US-20040192691-A1 | Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof | EURO-CELTIQUE S.A. | 2004-09-30 | — | — | US | disclosed |
| EP-1265866-A2 | ARYL SUBSTITUTED PYRIDINES, PYRIMIDINES, PYRAZINES AND TRIAZINES AND THE USE THEREOF | Euro-Celtique S.A. (LU) | 2002-12-18 | — | — | EP | disclosed |
| US-20020040025-A1 | Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof | PURDUE PHARMA L.P. | 2002-04-04 | — | — | US | disclosed |
| WO-2001068612-A2 | ARYL SUBSTITUTED PYRIDINES, PYRIMIDINES, PYRAZINES AND TRIAZINES AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043305-A1 | Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof | CACNA1S, CACNA1C, KYNU | TLR8 3263/4885SCN9A 1288/4885BCL2L1 3207/4885 |
| US-20040192691-A1 | Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof | CACNA1S, KYNU, CACNA1C | TLR8 3584/4885SCN9A 1388/4885BCL2L1 2422/4885 |
| US-20020040025-A1 | Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof | CACNA1S, KYNU, CACNA1C | TLR8 3584/4885SCN9A 1388/4885BCL2L1 2422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.